Latest / Deep Dive Ortho — Orthopaedic Surgery, AI & Digital Health Podcast. / Rotator Cuff Repair: The Role of Patch Augmentation

Transcript

Rotator Cuff Repair: The Role of Patch Augmentation · Deep Dive Ortho — Orthopaedic Surgery, AI & Digital Health Podcast.

0:00
Welcome to The Deep Dive, the show where we really
0:02
get into the details behind the headlines, focusing
0:05
on the most crucial insights from authoritative
0:07
sources. Glad to be here. Today, we're tackling
0:10
something that honestly affects so many people.
0:14
That... really persistent, nagging shoulder pain,
0:18
you know, the kind, I mean, where everyday things
0:20
suddenly feel impossible. Oh, absolutely. Reaching
0:23
up for something on a high shelf or even just
0:25
trying to get comfortable at night, it can be
0:27
incredibly disruptive. Exactly. We're talking
0:30
about rotator cuff tears and specifically the
0:32
really difficult ones, the ones surgeons often
0:35
call massive rotator cuff tears. These aren't
0:38
just minor strains. They can be genuinely debilitating
0:41
injuries, really impacting daily life, work,
0:44
sleep, everything. And repairing them has been,
0:47
well, a major challenge in orthopedics for a
0:49
long time, hasn't it? For decades, yes. Standard
0:52
surgical techniques, while they often work well
0:54
for smaller tears, they frequently struggle when
0:57
it comes to these really large, complex injuries.
1:00
Leaving patients sometimes with ongoing pain,
1:02
maybe limited movement, and even the possibility
1:04
of needing more surgery down the line? That's
1:07
the unfortunate reality for some, yes. Which
1:09
leads us to why we're doing this deep dive today.
1:11
Right. Our mission today is to explore a solution
1:14
that's been evolving rapidly and is frankly pretty
1:18
groundbreaking. Patch augmentation. Think of
1:21
it as adding a reinforcement to that torn tendon.
1:25
But it's more than just a physical patch. It's
1:27
often designed to be biologically active too.
1:29
So we want to unpack what these patches actually
1:32
are, how they're supposed to work. you know,
1:34
biomechanically and maybe even at a cellular
1:36
level to help the body heal itself. And crucially,
1:39
what the real -world impact has been. What does
1:42
the evidence tell us about how well they work
1:44
for patients? We'll look at the science, the
1:46
successes, and yeah, probably some of the setbacks,
1:49
too, because that's how medical innovation works,
1:51
right? It's rarely a straight path. Definitely
1:53
not. And our main guide for this discussion is
1:55
a really thorough comprehensive systematic review.
1:59
It's titled Rotator Cuff Repair with Patch Augmentation.
2:02
What do we know? Okay. It was published back
2:05
in October 2022 in the archives of bone and joint
2:08
surgery. And it's important to stress this isn't
2:11
just one study. Right. It's a review. It pulls
2:13
together lots of research. Exactly. It synthesizes
2:16
a huge amount of existing literature. It represents
2:18
the collective knowledge and experience of a
2:21
team of leading orthopedic specialists from various
2:24
places. And what's really valuable here for our
2:26
deep dive is that this specific review was co
2:29
-authored by a team of highly respected experts
2:31
in the field. Yes. Including Professor Mohammed
2:33
Elitmi Mom. His background in orthopedic surgery
2:36
and research, his work at places like Ashford
2:39
and St. Peter's NHS Foundation Trust, the Fortius
2:42
Clinic in London. It's extensive. His contributions
2:46
and those of his co -authors are really central
2:48
to understanding these complex challenges and
2:51
the innovations trying to address them. So their
2:54
expertise really provides the foundation for
2:56
everything we're going to discuss today. It sets
2:58
the stage for a really in -depth exploration.
3:00
Precisely. OK, so let's start by really defining
3:02
the scale of the problem, because understanding
3:04
the challenge helps us appreciate why things
3:06
like patch augmentation even came about. Absolutely.
3:09
The review makes it clear. Massive rotator cuff
3:12
tears remain a really significant hurdle in orthopedic
3:16
surgery. Even with all the tech advancements,
3:19
better instruments, refined techniques. Even
3:21
with all that. Despite decades of progress, the
3:25
healing rates for these bigger, more complex
3:28
tears are still, well, quite variable. Some patients
3:32
do great, others not so much. Exactly. And predicting
3:37
who will do well has been surprisingly difficult.
3:40
It's not always straightforward. So the goal
3:42
of the surgery itself is pretty clear, right?
3:44
You want to fix the tear. The primary objectives
3:46
are twofold. First, improve the patient's symptoms.
3:49
reduce pain, restore function, and second, improve
3:52
the structural integrity of the rotator cuff
3:54
itself. You want that tendon to heal back to
3:57
the bone properly. But here's where it gets complicated.
4:00
As the review points out, sometimes patients
4:02
feel better, their function improves. Even if
4:05
the repair fails structurally, meaning the tendon
4:07
actually re -tears later on. That seems counterintuitive.
4:10
How can you feel better if it's torn again? The
4:12
body is amazing at compensating. Other muscles
4:15
can take over. Inflammation might settle down
4:17
initially, but that underlying structural failure
4:20
is a major concern. And the rates of these re
4:23
-tears, especially for large and massive tears,
4:26
are quite high. Shockingly high in some studies.
4:29
The paper cites research reporting recurrent
4:31
tearing in as many as 94 % of these cases. 94%,
4:36
wow. It's a sobering statistic. It means that
4:39
even if things look good right after surgery,
4:41
Follow -up imaging, maybe an MRI a year or two
4:43
later, might show the tendon has torn again.
4:46
That really drives home the point you made. Feeling
4:48
better isn't always the same as being structurally
4:50
healed. It's a critical distinction. And it highlights
4:53
the need for solutions that promote genuine biological
4:56
healing, not just temporary symptom relief. The
4:59
review mentions more data, too. A big meta -analysis
5:02
from 2015. Yes, involving over 8 ,000 patients.
5:05
It found that overall, around 26 .6 % of all
5:08
rotator cuff repairs fail to heal structurally.
5:11
So roughly a quarter. That's a huge number across
5:14
the board. It really underscores the scale of
5:15
the problem we're talking about. It's not a news
5:17
issue. So the big question, then, is why? Why
5:20
do so many repairs fail to heal, especially these
5:23
larger ones? The paper points to a few key factors.
5:27
First and foremost is offer the tissue quality
5:30
itself. Meaning the tendon is already damaged.
5:33
Exactly. Patients with these massive tears often
5:36
have poor quality degenerative tendons with an
5:39
inadequate blood supply. Like trying to sew old
5:43
frayed fabric that doesn't get enough blood flow
5:45
to mend? That's a very good analogy. The basic
5:47
building blocks for healing just aren't optimal.
5:50
These tendons can be thin, fragile, they have
5:52
lost their elasticity. It makes getting a secure
5:55
repair that actually holds and heals incredibly
5:58
difficult. That makes sense. The material itself
6:00
is compromised from the start. Precisely. And
6:02
then you have patient demographics playing a
6:04
role too. Like age. Yes, the review notes that
6:06
healing outcomes are even worse in elderly patients,
6:10
with inferior rates of both healing and recurrence.
6:13
Which is entirely surprising, I guess. Healing
6:15
generally slows down as we age. Right. You have
6:17
general tissue degeneration, slower cell turnover,
6:21
maybe reduced blood flow, other health conditions
6:23
sometimes. It all stacks up against robust healing
6:26
in older individuals compared to, say, a young
6:29
healthy athlete with a traumatic tear. Okay,
6:31
so we have poor tissue quality, high re -tier
6:34
rates, factors like age. It sounds like a perfect
6:37
storm of challenges. What does this mean for
6:40
surgeons trying to get better results? It means
6:42
there's a relentless drive for something better.
6:45
The review emphasizes a really strong link. Those
6:48
with healed rotator cuff repair have better clinical
6:51
outcomes. So true healing equals better long
6:55
-term results. Generally, yes. When the tendon
6:58
genuinely heals and integrates properly, patients
7:01
tend to report less pain, they regain more strength,
7:04
and they're less likely to have the problem come
7:06
back years later. And that's the motivation behind
7:08
looking for new techniques and materials. Exactly.
7:11
The goal isn't just symptom management. It's
7:13
about promoting true biological structural healing
7:16
that lasts. Which leads us directly to patch
7:18
augmentation. Precisely. The whole idea behind
7:21
using a patch is that it can potentially do two
7:24
crucial things. First, It can mechanically reinforce
7:27
the repair, make it stronger right away, like
7:30
adding scaffolding. Taking the stress off the
7:33
initial repair. Exactly. And second, ideally,
7:35
it encourages biological healing. It might provide
7:38
a scaffold for new tissue to grow into, maybe
7:41
even deliver substances that stimulate the body's
7:44
own repair processes. It's trying to give the
7:46
body a helping hand, both physically and biologically.
7:49
Okay, so a helping hand with a patch. It sounds
7:51
simple, maybe like sticking a piece of tape over
7:53
the tear, but I'm guessing it's much more complex
7:56
than that. Oh, much more sophisticated, yes.
7:58
At its core, patch augmentation means using an
8:01
extra piece of material, the patch or graft,
8:04
to strengthen the rotator cuff repair. But it's
8:06
not just about strength, you said. No, the goal
8:08
is really twofold. It needs to provide that immediate
8:11
biomechanical support, protecting the fragile
8:13
repair while it starts to heal. But it also aims
8:16
to ideally induce native tissue growth. So it
8:19
encourages the body's own tissue to grow into
8:22
it. That's the hope. The ideal patch isn't just
8:25
a passive support. It's meant to be a biologically
8:27
active participant, a scaffold that encourages
8:30
regeneration and eventually integrates, becoming
8:34
part of the healed tendon. And this idea, using
8:37
patches, it's not brand new, is it? The review
8:40
mentions it has a history. That's a really important
8:42
point. While it feels very modern, surgeons were
8:45
experimenting with augmenting rotator cuff repairs
8:48
decades ago, even back in the 80s. What kinds
8:50
of materials were they using back then? Various
8:53
things. Some early animal -derived tissues, some
8:55
early synthetic materials. But those first attempts
8:58
often ran into major problems. Like what? The
9:01
big one was inflammation. The review describes
9:04
a profound inflammatory reaction in many cases.
9:07
Meaning the body saw the patch as foreign and
9:09
attacked it. Essentially, yes. The immune system
9:11
would mount a strong response trying to reject
9:14
or wall off this foreign material. And as you
9:17
can imagine, that led to poor outcomes, pain,
9:21
stiffness, and ultimately... the failure of the
9:23
augmentation. So a good idea in principle, but
9:26
the materials weren't quite right biologically.
9:29
Exactly. It was a really crucial lesson in biocompatibility.
9:32
The material has to work with the body, not against
9:34
it. So what changed? What allowed this concept
9:36
to make such a comeback? The real game changer
9:39
was technology, specifically breakthroughs in
9:42
how these materials, especially animal -derived
9:44
ones, are processed and purified. You mean cleaning
9:48
them up better? In essence, yes. Take animal
9:51
extracellular matrix, or ECM patches, that's
9:54
the natural scaffold around cells. Modern versions
9:57
go through much more modern and complete DNA
10:00
extracting procedures. Removing the animal DNA?
10:03
Primarily, yes. And other cellular components,
10:06
debris. Basically anything that the human immune
10:09
system is likely to react strongly against. Ah,
10:12
so less foreign stuff means less inflammation.
10:15
Precisely. This better processing leads to a
10:17
significantly reduced inflammatory response.
10:20
Often it's subclinical, meaning it's so mild
10:23
the patient doesn't even notice it, and it doesn't
10:25
interfere with healing. And that's why there's
10:27
this renewed interest, because the patches are
10:28
better tolerated now. That's a huge part of it.
10:31
It resulted in a renewed interest in rotator
10:34
cuff repair with patch augmentation. because
10:37
it made successful integration much more likely,
10:39
turning it from a risky experiment into a genuinely
10:42
viable option. Okay, so with these better materials,
10:46
what kinds of patches are actually being used
10:48
now? The review breaks them down into categories,
10:50
right? Yes, three main categories. First, you
10:51
have xenographs. Xeno meaning foreign or other,
10:55
so animal derived? Exactly. These come from animal
10:58
tissues. Common ones are porcine dermal grafts
11:01
from pigskin, or porcine small intestine submucosa,
11:04
known as SAS. There's also bovine pericardium
11:07
from cows, or even ovine foregut matrix from
11:11
sheep. And these are heavily processed to remove
11:12
the animal cells. Very heavily processed, decellularized,
11:16
sterilized. The goal is to leave just the structural
11:19
collagen framework. to act as a scaffold for
11:21
human cells to grow into. Okay, so that's xenografts.
11:24
What's the second category? That would be autografts
11:26
and allografts. These are human -derived. Auto
11:29
meaning self, allo meaning other, human. Correct.
11:33
Autografts use the patient's own tissue. Maybe
11:35
fascia lata from the thigh, part of the quadriceps
11:38
tendon, or even a flap of preosteum, the membrane
11:41
covering bone. The advantage there must be no
11:43
rejection, right? Virtually zero risk of rejection,
11:46
which is great. But the downside is you need
11:49
a second surgery site to harvest that tissue,
11:51
which brings its own potential problems. Pain,
11:55
weakness, longer surgery time. OK, so that's
11:57
autographs. What about allografts? Allografts
11:59
use tissue from a human donor, usually deceased.
12:02
A common one is a cellular human dermal graft
12:05
skin that's been processed to remove all the
12:08
donor cells, leaving just the collagen matrix.
12:10
So similar processing to the xenografts, but
12:13
starting with human tissue. Exactly. It avoids
12:16
the second surgery site for the patient, but
12:17
you still need rigorous screening and processing
12:20
to ensure safety and minimize any potential immune
12:23
response, though it's generally less vigorous
12:24
than when xenografts. Got it. And the third category,
12:27
the engineered ones. Synthetic grafts. These
12:29
are man -made materials, polymers like polyester.
12:32
polypropylene, polycarbonate polyurethane. Were
12:35
the early ones just like inert meshes? Pretty
12:38
much. Designed mostly for mechanical reinforcement.
12:41
But the really exciting developments now are
12:43
in things like nanoscaffolds. Nanoscaffolds?
12:47
That sounds high tech. It is. Using techniques
12:50
like 3D printing or electrospinning, researchers
12:53
can create scaffolds at the nanoscale that are
12:56
designed to very closely mimic the body's own
12:59
natural tissue structure, the ECM. The idea being
13:02
not just support, but actually guiding cell growth.
13:05
Precisely. To create an environment that encourages
13:07
cells to behave naturally, differentiate correctly,
13:10
and regenerate healthy tissue, it's moving towards
13:13
regenerative engineering. So xenograft, autograft,
13:16
allograft, synthetic, each with its own history,
13:19
pros, cons, and place in this search for the
13:22
perfect patch, I guess. That's a great way to
13:25
put it. And the review really digs into the scientific
13:27
and clinical evidence for each of these, trying
13:29
to see which ones are closest to achieving that
13:31
ideal. Okay, let's get into that science then.
13:33
We know the types, but how are they supposed
13:35
to work? Let's start with biomechanics. From
13:37
an engineering standpoint, what's the main goal?
13:40
The primary biomechanical aim is straightforward.
13:43
Make the repair stronger. You want to construct
13:45
the tendon, plus the patch, that can handle significantly
13:49
more load than the pendant repaired on its own.
13:52
Why is that initial strength so critical? because
13:54
the native tendon right after being sutured is
13:57
incredibly weak and vulnerable. normal shoulder
14:00
movements could potentially re -tear it. The
14:03
patch acts like an internal brace, shielding
14:06
the repair site from excessive stress during
14:08
that crucial early healing phase. Like a protective
14:11
shield while the real healing happens underneath.
14:14
Exactly. It provides a window for the biological
14:16
processes to kick in without the repair being
14:19
immediately compromised by mechanical forces.
14:21
And does the lab evidence back this up? Do these
14:24
patches actually make the repair stronger? Yes.
14:27
Generally they do. Lab studies, often using cadaver
14:30
shoulders, which allow for control testing, have
14:33
shown that synthetic patches, allografts, and
14:36
the dermal xenografts, like the porcine ones,
14:38
have all been shown to significantly increase
14:40
construct strength and load to failure rates.
14:43
Meaning they can take more force before breaking.
14:45
Correct. Which is very encouraging for protecting
14:47
the repair early on. However, it's not universal.
14:51
Some materials, like that porcine SIS we mentioned,
14:54
have shown less favorable outcomes biomechanically.
14:59
These weren't as strong. Okay, so strength is
15:01
good, but the review mentions this fascinating
15:04
concept, the Goldilocks problem almost. You don't
15:07
want it too strong. That sounds weird. It does
15:10
sound counterintuitive, but it's a really critical
15:12
point called stress shielding. Stress shielding.
15:15
Explain that. Okay, imagine you put a ridiculously
15:18
strong, rigid metal plate on a broken bone. That
15:21
plate might take all the load, shielding the
15:24
bone itself from the normal stresses it needs
15:26
to stimulate healing and remodeling. The bone
15:29
might not heal properly or could even weaken
15:31
over time because this is not being worked. Ah,
15:34
I see. The tissue needs some stress to heal correctly.
15:37
Exactly. If the patch is too stiff and strong
15:39
relative to the healing tendon, it can carry
15:41
too much of the load. This prevents the tendon
15:44
from getting the mechanical signals it needs
15:46
to heal robustly and integrate with the patch.
15:48
New tissue might not grow into the patch properly.
15:51
So too strong is bad, but obviously too weak
15:54
is also bad because it just fails. Precisely.
15:57
If it's too weak, it doesn't provide enough protection
15:59
and fails prematurely. So the ideal patch has
16:02
to hit that sweet spot. Strong enough initially,
16:04
but then what? What's the long -term goal for
16:07
how it behaves? The real challenge. The ultimate
16:09
goal. is to create a graft that provides that
16:12
initial support but also actively encourages
16:16
tissue infiltration and subsequent incorporation.
16:20
Becoming part of the body. Ideally, yes, with
16:23
desirable properties more similar to the native
16:25
rotator cuff. The Dream is a patch that remodels
16:28
over time, integrates fully, and eventually becomes
16:31
biologically and functionally indistinguishable
16:34
from a native tendon. True regeneration. not
16:37
just a permanent reinforcement. Okay, that covers
16:39
the mechanics. What about the histology? What's
16:42
happening at the microscopic tissue level? Are
16:44
we seeing this integration happen in human studies?
16:46
Well, that's where the data gets a bit thinner.
16:48
The review notes there are limited histological
16:50
studies investigating patch use for rotator cuff
16:53
repair in humans. Why so few? Is it hard to get
16:56
tissue samples? Very hard, ethically and practically.
16:59
You generally wouldn't do a biopsy on a healing
17:01
tendon unless there was a clinical reason for
17:04
re -operation. So much of our detailed histological
17:07
understanding still comes from animal studies.
17:10
Which are useful, but not always a perfect match
17:13
for humans. Correct. They give us important clues,
17:16
but we have to be cautious extrapolating directly.
17:19
So based on the available studies, human and
17:22
animal, what's the verdict at the tissue level?
17:24
Do patches promote good healing? It's quite mixed,
17:27
honestly. The review states there are variable
17:30
healing outcomes with patch augmentation depending
17:33
on the type of graft used. So it really depends
17:35
on the specific material. Yes, and frustratingly,
17:38
there's even disagreement among studies using
17:40
the same material, which highlights how many
17:43
factors are at play. Surgical technique, patient
17:45
biology, how the histology was assessed. It's
17:49
complex. But surely there must be some positive
17:51
signs. Any materials that consistently show good
17:54
tissue integration. Oh yes, definitely some promising
17:57
findings. Human dermal allograft, for example,
18:00
has generally performed well in histological
18:02
studies. They see good signs like cellular infiltration,
18:05
meaning the patient's own cells are moving into
18:07
the graft, revascularization, new blood vessels
18:10
forming, and evidence of new tendon formation.
18:13
That sounds like exactly what you'd want to see.
18:16
It is. Porcine dermal grafts have also yielded
18:19
encouraging outcomes in animal studies, showing
18:21
similar positive signs of integration. And autografts,
18:24
being the patient's own tissue, also show encouraging
18:27
histological outcomes in animal models with improved
18:30
tendon healing. These are all good indicators
18:33
that biological incorporation can happen. OK,
18:36
but what about the other side of the coin? Any
18:37
materials that looked less impressive under the
18:39
microscope? Yes. That porcine SIS Again, despite
18:44
some early animal optimism, human studies reported
18:47
unsatisfactory outcomes, histologically, often
18:50
showing inflammation, poor celling growth, not
18:53
much new tissue. So the poor clinical results
18:55
matched the poor tissue integration. Seems so.
18:58
And some of the older synthetic grafts, like
19:01
polyester, were often seen histologically as
19:04
just remaining inert foreign bodies. They reinforced
19:07
mechanically for a while, but didn't really integrate
19:09
or promote new tissue growth within their structure.
19:12
What about adverse reactions? You mentioned the
19:15
inflammation issues with early patches. Is that
19:17
still a major concern with the modern ones? It's
19:19
always a consideration, but the situation has
19:22
improved dramatically. While adverse reactions
19:25
are now considered generally rare, they have
19:27
been reported even with newer materials. Like
19:30
what? Well, we already discussed the severe inflammatory
19:33
reactions to porcine SIS. But interestingly,
19:36
one study by Rashid et al. found that even some
19:39
otherwise promising human allografts and porcine
19:42
dermal grafts could occasionally cause significant
19:45
disruption of the ECM of the underlying native
19:47
tendon. Meaning they could actually damage the
19:49
tendon they were supposed to help. In some cases,
19:51
yes, leading to more fragile disorganized tissue
19:54
underneath. It highlights how complex the host
19:56
-graphed interaction is, and that even generally
19:59
well -polarated materials aren't perfect in every
20:01
single instance. But the review stresses that
20:04
most of the severe reactions were seen with the
20:06
older, less -purified models, right? Correct.
20:09
And that's a crucial takeaway. The paper explicitly
20:12
says most of these adverse reactions have investigated
20:15
the earlier models. Thanks to the improved processing,
20:19
especially the better DNA extraction for animal
20:21
ECM patches, the inflammatory responses now are
20:24
usually much milder, often subclinical. And these
20:27
milder responses don't seem to hurt the clinical
20:30
outcome. Generally, they seem not to affect clinical
20:33
outcomes in most patients. It really underscores
20:36
how critical that manufacturing and purification
20:38
process is, not just for integration, but for
20:41
basic safety and tolerance. So the lab work,
20:43
the biomechanics, the histology, they give us
20:46
a foundation. But the ultimate test is how these
20:48
patches perform in real patients, isn't it? How
20:51
do they actually affect recovery and long -term
20:53
results in the clinic? Exactly. That's the crucial
20:55
next step. And interpreting that clinical data
20:57
as the review makes very clear is very challenging.
21:01
OK. So why is it so challenging to get clear
21:04
answers from the clinical studies? If surgeons
21:07
are using these patches, shouldn't we know by
21:10
now what works best? You'd think so, but there
21:13
are several complicating factors. Firstly, there's
21:15
just immense variety of implantation approaches,
21:18
surgical techniques, and patches used. So different
21:21
surgeons doing things differently. Exactly. Different
21:23
patch materials, different ways of fixing them,
21:26
open versus arthroscopic surgery, even different
21:28
rehab protocols afterwards. All this variation
21:31
leads to Highly variable outcomes that are really
21:35
difficult to compare meaningfully across studies
21:38
like comparing apples oranges and maybe pears
21:41
pretty much Secondly many of the existing studies
21:45
are relatively small or they're not direct comparisons
21:47
between different patch types Often they have
21:50
only a small number of comparative studies or
21:52
research investigating each patch type often
21:55
with a short follow -up period So we don't have
21:57
enough big long -term head -to -head trials yet.
22:00
Not nearly enough You need those kinds of studies
22:02
to draw really definitive conclusions. So, given
22:05
all that variability, what do we know? What's
22:08
the range of results people are seeing? It's
22:10
incredibly wide. A meta -analysis mentioned in
22:12
the review by Uni et al. looked at retier rates
22:15
after patch augmentation. They found the rates
22:18
ranged anywhere from a really good 8 .3 % all
22:22
the way up to a very disappointing 73 .4%. Wow,
22:25
8 % to 73%, that's a massive difference. What
22:28
determines where a study falls in that range?
22:31
It depends heavily on the graft type indication
22:33
and technique. Which patch was used? Why was
22:36
it used for a primary repair, a revision, an
22:38
irreparable tear? How was it put in? All these
22:41
factors influence the outcome dramatically. Okay,
22:43
let's try to break it down by type then. Starting
22:45
with xenografts, the animal ones. The review
22:48
suggested pretty mixed results there, a real
22:50
learning process. Very mixed, yes. A clear example
22:53
is porcine small intestine subucosa, the SIS
22:56
patch. It consistently showed poor results in
22:58
clinical trials. Like that big randomized trial
23:00
you mentioned? Exactly. Iannotti et al. did a
23:04
randomized control trial, a strong study design,
23:07
and found no significant improvement with SIS.
23:10
In fact, healing rates were worse than the SIS
23:12
group. Only 27 % healed compared to 60 % of the
23:16
control group without a patch. Worst healing.
23:18
That's the opposite of what you want from an
23:20
augmentation. Absolutely. Other studies by Bryant
23:23
et al. and Slamberg et al. found similar things.
23:25
No benefit. poor radiological outcomes, and unsatisfactory
23:30
clinical outcomes, with Glambrook reporting a
23:32
91 percent retire rate. So SIS was pretty much
23:36
a dead end for a rotator cuff repair. It seems
23:38
that way based on the evidence. It really illustrates
23:41
that early promise in animal models doesn't always
23:43
translate to human success. But what about other
23:45
zener grafts? Did the porcine dermal grafts fare
23:48
better? Much better, yes. Porcine dermal grafts
23:51
have shown considerably more promise clinically.
23:53
What kind of results are we talking about? Some
23:54
studies are quite impressive. Avanzi et al. reported
23:57
a healing rate of 97 .6 % in the patch group,
24:00
which is remarkably high compared to just under
24:02
60 % in their control group. They also saw better
24:05
tendon thickness and function. That's a huge
24:07
difference. It is. Castagna et al. found significant
24:10
functional improvements even when using these
24:13
patches for recurrent tears as a salvage option.
24:17
Latermin et al. also reported significantly better
24:20
functional scores. So a much more positive picture
24:23
for this type of xenograft. And this is where
24:25
the review highlights work involving Professor
24:27
Imam and his colleagues, right? Their research
24:30
seems to back up the promise of these porcine
24:33
ECM graphs. Yes, absolutely. The paper specifically
24:36
cites studies by Consiglier et al., a research
24:39
group where Professor Mohammed Imam is a co -author.
24:41
Their work in 2017 and 2021 looked at a denatured
24:45
porcine ECM patch. And what did they find? They
24:48
found significantly improved functional outcomes
24:50
and pain scores compared to baseline. And importantly,
24:53
their 2021 study reported lower structural failure
24:56
rates, only about 15 .9 % re -tiers, which compared
25:00
favorably to historical controls for similar
25:02
large tiers repaired without a patch. So their
25:05
own research directly contributes to this positive
25:07
evidence base for certain xenografts? Precisely.
25:10
It's a clear example of how the author's expertise,
25:14
including Professor Immam's, has directly shaped
25:17
our understanding and provided key data supporting
25:19
these techniques. That's great to see. But even
25:22
with these promising results, is it perfect?
25:25
Are there any caveats for the porcine dermal
25:28
graphs? As always, in medicine there's nuance.
25:31
One study by Floriat et al. looks specifically
25:34
at patients over 60 years old. They found that
25:37
in this older group, the porcine dermal graft
25:39
didn't lead to significantly better functional
25:42
scores or lower retier rates compared to standard
25:45
repair. Suggesting that age might still be a
25:47
limiting factor even with a good patch. It might
25:50
be, yes. Or perhaps the specific way it was used
25:52
in that study. It just shows that effectiveness
25:54
can still vary and patient selection remains
25:57
really important. Okay, let's move to the human
25:59
-derived grafts. Autographs and allografts. The
26:02
reviews seem particularly positive about a cellular
26:05
human dermal allografts. Are they emerging as
26:07
a leader? The evidence certainly points in that
26:10
direction. They appear to be the most consistently
26:12
promising type based on current data. What makes
26:14
the evidence so strong? Several well -designed
26:17
studies show good results. Barber et al. did
26:20
a prospective randomized study again, high quality
26:23
evidence comparing standard repair -to -repair
26:25
augmented with a human dermal allograft. And
26:28
the results? Strikingly different. 85 % of patients
26:33
in the augmented group had an intact cuff on
26:36
MRI compared to only 40 % in the control group.
26:39
They also had better functional outcomes and,
26:41
importantly, no complications related to the
26:44
graft itself. 85 % versus 40 % healed is a big
26:47
deal. It really is. And other studies by Jilal,
26:50
Petrie, Hall, and others have reported similarly
26:53
positive outcomes, creating a consistent pattern
26:55
of success for this specific type of allograft.
26:58
Was there one study that directly compared different
27:00
patch types and singled out the human dermal
27:02
allograft? Yes, a study by Lusinger et al. in
27:05
2016 did just that. They compared a xenograft,
27:08
an allograft, specifically graft jacket, a human
27:11
dermal product, and a synthetic graft. Their
27:13
conclusion, the human dermal allograft yielded
27:16
the best outcome scores. That's pretty compelling
27:18
comparative evidence. It is. It really suggests
27:20
that, based on what we know now, this material
27:22
might be leading the pack. What about autographs
27:25
using the patient's own tissue? Are they used
27:27
often? Less often. Mainly because of that second
27:29
surgical site needed for harvesting. That adds
27:31
risk, pain, and recovery time. But they are still
27:35
an option, maybe for specific situations? Yes.
27:38
Crucial, perhaps, for patients who object to
27:40
animal or donor tissue for personal or religious
27:42
reasons. And they could work well. Mori, et al.,
27:46
showed significantly better outcomes, using fasciolata
27:49
autographs for tears deemed irreparable otherwise.
27:52
But the donor site is a real concern. It can
27:54
be. Tempelair, et al., reported good shoulder
27:57
outcomes, using quadriceps tendon autographs,
28:00
but also noted high rates of complications at
28:02
the donor site in the thigh. It's a trade -off.
28:05
And there's a cautionary tale about autographs
28:07
too, isn't there? Something about a periosteal
28:09
flap. Ah, yes, the humoral periosteal flap. Initially,
28:13
back in 2006, Scheibel et al. reported promising
28:15
results using this flap of bone membrane from
28:18
the upper arm bone. Looked good at first. Yes,
28:20
but then a later study by Hollein et al. in 2019,
28:23
with longer follow -up, found no improvement
28:25
in healing response and actually unsatisfactory
28:28
clinical outcomes. So the initial promise didn't
28:30
hold up over time. Exactly. It led the researchers
28:33
to conclude they could no longer recommend this
28:35
approach. It's a vital lesson. Short -term results
28:38
aren't always predictive, and medical evidence
28:40
is constantly evolving based on longer -term
28:42
data. A really important reminder. OK, last category.
28:46
Synthetic and biologically enhanced graphs. What's
28:50
their clinical story? The early synthetic graphs,
28:53
like some polyesters, generally had poor long
28:56
-term outcomes. That study by Renevo et al. with
28:59
nearly 20 -year follow -up found poor results,
29:02
and disturbingly, 75 % of patients developed
29:05
cuff tear arthropathy. Severe arthritis caused
29:08
by the failed repair. Yes, likely because the
29:11
graft didn't integrate biologically, failed mechanically
29:13
over time, and led to abnormal joint mechanics
29:16
and degeneration. But newer synthetics are showing
29:19
more potential. They are. Material science has
29:21
advanced. Chionpi et al. found significantly
29:24
improved function and retire rates using a newer
29:26
polypropylene patch. And Kai et al. explored
29:30
3D collagen scaffolds, finding better retire
29:32
rates and tendon -bone integration in the short
29:34
term. Do these newer synthetics still face that
29:38
stress shielding problem? It remains a critical
29:41
challenge, yes. Synthetics often have very different
29:44
mechanical properties than native tendon, usually
29:47
much stiffer. This mismatch can lead to that
29:50
stress shielding effect, where the patch carries
29:52
too much load, potentially hindering the natural
29:54
healing and remodeling of the tendon itself.
29:57
Finding that perfect balance of initial support
29:59
and eventual load sharing is key. What about
30:01
the really futuristic sounding ones, the nanoscaffolds?
30:05
They've recently garnered more interest because
30:06
their design at the nanoscale aims to mimic the
30:09
natural ECM much more closely. The theory is
30:12
this promotes better cell behavior and tissue
30:15
regeneration. And is it working in practice?
30:17
One study by Kim et al found superior tendon
30:21
healing in animals. But the exact reasons why
30:23
are still poorly understood. The big caveat is
30:26
that we're still waiting on significant clinical
30:28
trials at humans for these cutting -edge materials.
30:31
Huge promise, but early days clinically. And
30:34
finally, what about combining graphs with biological
30:37
boosters, stem cells, growth factors? That's
30:40
a really exciting area, trying to get the best
30:42
of both mechanical support and biological stimulation.
30:45
But the clinical results so far are quite mixed.
30:48
Some positive, some not. Exactly. Jang et al.
30:52
had good results combining a scaffold with mesenchymal
30:55
stem cells in preclinical models. But Mensch
30:58
et al. reported poor functional results when
31:02
they tried adding PRP and bone marrow aspirate
31:05
sources of growth factors in stem cells to a
31:08
human dermal allograft in patients. So just adding
31:10
biology isn't a guaranteed fix. It's... more
31:14
complicated. It seems so. The timing, the dose,
31:16
the specific factors, how they interact with
31:18
the graft material, it all likely matters. There's
31:21
lots of encouraging preclinical research, but
31:24
the review concludes we urgently need well -designed
31:27
prospective clinical trials to figure out how
31:29
to make biological enhancement work reliably
31:31
in humans. So a lot learned, but still much to
31:34
figure out about the materials themselves. And
31:35
as you said, the material is only half the story.
31:38
How it's put in surgically is just as crucial.
31:40
Absolutely. A perfect patch of material is useless
31:42
if you can't get it in the right place and secure
31:44
it properly. How has the surgical approach changed
31:47
over time? Were these always done arthroscopically?
31:49
No. Initially, many surgeons used traditional
31:52
open surgery for these complex repairs and augmentations.
31:56
Bigger incision, more dissection. But now...
31:58
Now, with huge advancements in arthroscopic technology
32:02
and skills, minimally invasive techniques are
32:05
much more common. Pash augmentation done arthroscopically
32:09
have gained popularity in recent years. Through
32:11
those small keyhole incisions with a camera.
32:14
Exactly. Less tissue trauma, potentially less
32:16
pain, faster recovery. The review kind of implicitly
32:20
shows this evolution in its figures moving from
32:23
simpler concepts to more refined arthrostopic
32:26
steps for deploying and fixing the patch. What
32:28
were some of the early arthroscopic techniques
32:30
like? Often they involved just overlaying the
32:33
patch on top of the repaired tendon. It was mainly
32:35
secured laterally at the bone attachment site
32:37
without strong fixation on the inner medial side
32:40
closer to the muscle. And why was that medial
32:43
fixation found to be so important? This seems
32:45
like a key insight highlighted in the review,
32:47
particularly involving Professor Imam's group.
33:04
So it needs to be fixed to the healthy tendon.
33:10
medially as well as the bone laterally. Precisely.
33:13
If it's only six laterally, it can't effectively
33:16
bridge the gap and distribute the forces. The
33:18
repair underneath might still see too much stress.
33:21
It needs that kenshin band effect across the
33:23
whole repair. And this led Professor Imam and
33:25
his colleagues to develop a specific technique.
33:28
the pullover technique. Yes, that's a fantastic
33:31
example of their direct contribution to surgical
33:33
innovation. The review explicitly mentions the
33:36
pullover technique, described in a 2017 paper
33:38
by Narvani, Imam, Polyzoius, and others. How
33:42
does that work differently? Instead of just laying
33:44
the patch flat on top, this technique involves
33:46
strategically passing sutures to pull over or
33:49
wrap the patch around the medial edge of the
33:52
remaining healthy tendon cuff and securing it
33:54
there, as well as laterally. It creates a more
33:57
compressed encompassing, and biomechanically
34:00
sound augmentation. So a more sophisticated way
34:03
to achieve that crucial load sharing. Exactly.
34:07
It represents a significant step forward from
34:09
simple overlay techniques directly addressing
34:12
that biomechanical need for medial stability.
34:14
Are there other modern techniques being used
34:16
now as well? Yes, the field keeps innovating.
34:19
Surges now use special deployment devices. Think
34:22
of them like sophisticated inserters to help
34:24
position the patch accurately in the tight joint
34:27
space arthroscopically. Making it easier and
34:29
more reliable. That's the goal. And fixation
34:32
methods have evolved, too. They might use special
34:34
staples made of materials like polylactic acid
34:36
or peak to secure the patch medially, anteriorly,
34:40
and posteriorly, getting multiple points of fixation.
34:43
But is there one single best way to do it now?
34:46
Not yet. The review notes there's currently no
34:49
consensus on any single method that should be
34:51
used. It's still an area of active research,
34:54
debate, and refinement. Different surgeons might
34:57
prefer different techniques depending on the
34:58
tear, the patch, and their own experience. The
35:01
review also mentions that advancements in other
35:04
complex shoulder surgeries might be helping push
35:06
patch augmentation forward. Yes, there's definitely
35:09
a crossover effect. Procedures like superior
35:12
capsular reconstruction, or SCR, have become
35:15
more popular for irreparable tears. And SCR also
35:18
uses patches. Often, yes. A patch is used to
35:21
reconstruct the top part of the joint capsule
35:23
to restore stability. The development of better
35:25
instruments, anchors, and techniques specifically
35:28
for SCR has been a contributing factor to improving
35:31
the tools available for patch augmentation of
35:33
the rotator cuff too. They learn from each other.
35:36
And Professor Imam has been involved in SCR research
35:39
as well. Yes, the review mentions he co -authored
35:41
a systematic review on SCR back in 2019, showing
35:44
his broad expertise across complex shoulder reconstruction.
35:48
There's also this intriguing belt and braces
35:51
or hamburger technique mentioned, also linked
35:53
to Professor Imam's group. What's that about?
35:56
That's a really cutting edge concept described
35:58
in a paper by Memmon, Imam, and colleagues in
36:01
2020. The idea is to combine both patch augmentation
36:06
of the rotator cuff and an SCR procedure. Two
36:09
patches essentially, one on top, one maybe underneath
36:12
or acting as the capsule. Kind of like that,
36:14
hence the hamburger analogy. You have the repaired
36:17
cuff. augmented with a patch, the belt, and then
36:20
an SCR construct as well, the braces. The goal
36:23
is maximum stability and healing potential for
36:26
the most severely damaged shoulders. Has that
36:28
been proven in clinical trials yet? Not yet.
36:31
The review states that clinical trials are yet
36:33
to be completed. But it represents the kind of
36:36
innovative thinking happening at the forefront,
36:38
combining techniques to tackle the toughest problems
36:40
driven by experts like Professor Imam and his
36:43
collaborators. So materials are improving, techniques
36:46
are getting more sophisticated. It feels like
36:48
we're definitely heading in the right direction.
36:50
But what are the big remaining questions? What
36:52
does the road ahead look like? Well, one of the
36:54
really fascinating points the review brings up
36:56
is this persistent disconnect we sometimes see.
36:59
The radiological outcomes, what an MRI or ultrasound
37:03
shows about the tendon healing, do not always
37:05
match the clinical outcomes the patient experiences.
37:09
You mentioned this earlier, patients feeling
37:11
better even if the scan shows a retier. Exactly.
37:15
Especially with larger tears or in older patients,
37:17
many still do well clinically. Their pain is
37:21
better, function is improved, even if the structural
37:23
repair isn't perfect on imaging. So does that
37:26
mean the structural healing doesn't matter as
37:28
much as we thought? Not necessarily. While symptom
37:32
relief is paramount, the authors, including Professor
37:35
Imam, strongly argue that the evidence still
37:37
shows those with well -healed tendons do have
37:40
superior clinical outcomes in the long run. better
37:43
durability, maybe less chance of problems later.
37:46
That's the idea. A truly healed tendon is likely
37:49
to provide more sustained pain relief, better
37:51
strength, and be less prone to later degeneration
37:54
or retearing compared to one that hasn't healed
37:56
structurally, even if the patient feels okay
37:58
initially. So the ultimate goal isn't just good
38:01
clinical outcomes anymore. The ambition for the
38:04
next decade, as the paper puts it, should be
38:06
to not only have good clinical outcomes but also
38:10
improve the tendon healing rate. It's about achieving
38:13
both making patients feel better and ensuring
38:15
the underlying biology is truly restored for
38:18
long -term success. How do the experts, like
38:21
Professor Imam and his co -authors, propose we
38:23
get there? The review outlines some key strategies,
38:26
right? Three pillars for future progress. Yes,
38:29
they lay out a clear roadmap. Pillar number one
38:31
is the continued development of patches resembling
38:34
native tissue. Creating graphs that mimic natural
38:37
tendon as closely as possible in all aspects,
38:40
mechanically, structurally, biologically. To
38:42
overcome stress shielding and encourage seamless
38:45
integration. Exactly. If the patch behaves almost
38:47
identically to the native tissue, the body is
38:49
more likely to accept it, remodel it, and integrate
38:52
it fully. Okay, pillar one. Better mimicking.
38:54
What's biller two? Biological enhancement of
38:57
patches. This is about actively stimulating healing,
39:00
using things like stem cells, growth factors,
39:02
or other bioactive molecules incorporated into
39:04
the patch itself. Moving beyond a passive scaffold
39:07
to an active delivery system for healing signals.
39:10
Precisely. Giving the body's repair processes
39:12
a direct boost right at the site of injury. It's
39:15
about actively promoting regeneration at the
39:18
cellular level. And the third pillar. This sounds
39:20
more practical. Surgical. It is. Improved instrumentation.
39:25
Developing better, more intuitive tools for surgeons
39:27
to arthroscopically delivering and stabilizing
39:30
the patches consistently and reliably without
39:33
adding significantly to surgical time. Because
39:35
even the best patch is useless if it's too hard
39:37
to put in correctly. Absolutely. Surgical efficiency,
39:41
reproducibility, and minimizing operative time
39:43
are critical for any technique to be widely adopted
39:46
and successful in the real world. Ease of use
39:48
matters. Right. So combining those three pillars,
39:51
mimicking native tissue, biologically enhancing
39:54
it, and making it easy to implant that leads
39:56
to the vision of the perfect patch. That's the
39:58
ultimate goal described in the paper, a patch
40:00
that provides the right initial biomechanical
40:03
reinforcement actively, biologically promotes
40:07
healing and cellular infiltration without an
40:10
adverse tissue reaction, and is also easy to
40:13
deliver surgically and stabilize it arthroscopically.
40:15
It's a tall order, but it sounds like the direction
40:18
the field is heading. It is. It's about creating
40:20
a solution that works on all levels, mechanically,
40:23
biologically, and practically. But despite all
40:26
this progress and exciting potential, are there
40:28
still big unanswered questions, ongoing debates?
40:32
Oh, definitely. The review acknowledges there's
40:35
still debate over the superiority of patch augmentation
40:38
over standard repairs in terms of healing improvement,
40:41
especially when you consider all types of tiers
40:43
and patients. It's not yet definitively proven
40:46
better for everyone. which means we need more
40:48
research. Urgently. The paper concludes with
40:51
a very strong call for high -quality prospective
40:54
clinical trials. We need large, well -designed
40:57
studies that directly compare different graft
40:59
types against each other and against standard
41:01
repair, looking carefully at both clinical and
41:04
radiological outcomes. Randomized controlled
41:06
trials, the gold standard. Exactly. They need
41:09
to be sufficiently powered to give clear answers
41:11
and randomized to avoid bias. That's how we'll
41:15
really know which patches work best, for which
41:17
patients, and using which techniques. So the
41:19
journey is far from over, even with these incredible
41:21
advancements. Far from over, but incredibly promising.
41:25
Patch augmentation is, without doubt, an exciting
41:27
topic. It represents a major step forward, and
41:30
as the review predicts, it will surely be the
41:33
subject of many scientific discussions in the
41:35
next decade. The potential for truly improving
41:38
how we treat these debilitating injuries is immense.
41:42
Wow, what a fascinating deep dive. We've really
41:45
covered a lot of ground today. We started with
41:46
the significant challenge of massive rotator
41:49
cuff tears, those high re -tier rates, the difficulties
41:51
in healing. Then we traced the evolution of patch
41:54
augmentation from early problematic attempts
41:56
to the modern, better tolerated xenografts, allografts,
42:00
and a potential of synthetics. We explored the
42:02
intricate science, the biomechanics of load sharing
42:04
and stress shielding, the histological evidence
42:07
of tissue integration, both good and bad. And
42:10
we looked at the real world clinical data. which
42:13
is complex but shows real promise for certain
42:15
materials like human dermal allografts and modern
42:18
porcine dermal grafts, including the important
42:21
contributions from research involving Professor
42:23
Mohammed Imam and his team. We also touched on
42:26
how surgical techniques have evolved, becoming
42:28
less invasive and more sophisticated, with innovations
42:31
like medial stabilization and the pullover technique,
42:34
again highlighting Professor Imam's contributions
42:37
to the field. And finally, we looked ahead at
42:39
the ongoing quest for the perfect patch. one
42:42
that mimics native tissue, boosts biology, and
42:45
is easy for surgeons to use while acknowledging
42:47
the crucial need for more high -quality trials.
42:50
The key takeaway seems to be that patch augmentation,
42:53
used selectively and with the right materials
42:55
and techniques, holds real potential to improve
42:57
outcomes for patients struggling with these difficult
43:00
tiers. But it's a field that's definitely still
43:03
evolving. Maturing, yes, with lots more to learn.
43:06
So... As you, our listener, consider the incredible
43:10
complexity of the human shoulder and the sheer
43:13
ingenuity of the medical science trying to repair
43:15
it, maybe you're left wondering something similar
43:18
to what I am. How close are we, really, to creating
43:21
truly regenerative solutions, like living biological
43:25
spare parts that fully integrate? And what other
43:27
parts of the body might benefit from this kind
43:29
of approach, pushing the boundaries of healing
43:32
and regeneration? Fascinating thought. Thank
43:34
you for joining us on the Deep Dive. We hope
43:36
this exploration has sparked your curiosity.
43:39
Until next time.